Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Puma Biotechnology Inc maintains a gross margin of 69.35%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 22.67%, while the net margin is 17.81%. These profitability ratios, combined with a Return on Equity (ROE) of 27.97%, provide a clear picture of how effectively PBYI converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PBYI competes directly with industry leaders such as ACIU and AMRN. With a market capitalization of $290.00M, it holds a significant position in the sector. When comparing efficiency, PBYI's gross margin of 69.35% stands against ACIU's 100.00% and AMRN's 47.07%. Such benchmarking helps identify whether Puma Biotechnology Inc is trading at a premium or discount relative to its financial performance.
